Article

The impact of Fulvestrant on Estrogen Receptor-Driven Chromatin Dynamics in Breast Cancer

2025-06-06

Abstract excerpt

<title>Abstract</title> <p>Background Epigenetic dysregulations are linked to various diseases, including cancer. Among them, breast cancer is the second leading cause of cancer-related deaths in women with 50% of mortalities attributable to estrogen receptor-positive (ER+) tumors. Endocrine therapies targeting the Estrogen Receptor (ER) such as Tamoxifen, Fulvestrant and Aromatase inhibitors, are widely used in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 65211891-a6f6-5fb4-b71b-e91b4a675ca3
DOI: 10.21203/rs.3.rs-6779056/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The impact of Fulvestrant on Estrogen Receptor-Driven Chromatin Dynamics in Breast CancerDOI 10.21203/rs.3.rs-6779056/v1Read

VGLL1 drives therapy resistance in estrogen receptor positive breast cancerSemantic proximity Read

Genome-wide analysis uncovers high frequency, strong differential chromosomal interactions and their associated epigenetic patterns in E2-mediated gene regulationSemantic proximity Read

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancerSemantic proximity Read

Cracking the estrogen receptor's posttranslational code in breast tumors.Semantic proximity Read

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.Semantic proximity Read

The natural L370F ERα Variant Confers Endocrine Resistance and Sensitivity to ATRA in Metastatic Breast Cancer CellsSemantic proximity Read

Parallel Factor ChIP Provides Essential Internal Control for Quantitative Differential ChIP-SeqSemantic proximity Read

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complexSemantic proximity Read

Amplification of WHSC1L1 regulates expression and estrogen‐independent activation of ERα in SUM‐44 breast cancer cells and is associated with ERα over‐expression in breast cancerSemantic proximity Read

Clinical, pathological and molecular predictors of Fulvestrant long-term benefit in Hormone Receptor-positive / HER2 negative advanced breast cancerSemantic proximity Read

A novel HER2 gene body enhancer contributes to HER2 expressionSemantic proximity Read

FoxA1 is a Key Mediator of Hormonal Response in Breast and Prostate CancerSemantic proximity Read